Le Lézard
Classified in: Health
Subjects: NPT, DIS

More Than 1,000 Partners Across 85 Countries Join World Thrombosis Day Campaign to Reduce Death and Disability from Thrombosis


CHAPEL HILL, N.C., Oct. 13, 2017 /PRNewswire-USNewswire/ -- The World Thrombosis Day (WTD) Campaign, led by the International Society on Thrombosis and Haemostasis (ISTH), today announced that more than 1,000 partners across 85 countries are now participating in a united effort to reduce death and disability from thrombosis (commonly known as blood clots) ? a more than five-fold increase since the campaign launched in 2014.

"One in four people worldwide die from conditions caused by thrombosis, though many cases are preventable," said Gary Raskob, PhD, Chairman of the World Thrombosis Day Steering Committee, and Dean of the College of Public Health at the University of Oklahoma Health Sciences Center. "We are grateful for the extraordinary support of our global campaign partners who work year-round in their communities to raise awareness of thrombosis, the risk factors, and the signs and symptoms ? an effort that ultimately helps save lives."

Recognized annually on 13 October, WTD is a global movement that puts a spotlight on thrombosis ? the underlying cause of the world's top three cardiovascular killers: heart attack, stroke and venous thromboembolism (VTE). WTD 2017 focuses on hospital-associated VTE, given up to 60 percent of all VTEs occur during or after hospitalization and VTE is the leading preventable cause of hospital death.

To learn more about WTD and its campaign partners, visit WorldThrombosisDay.org.

About World Thrombosis Day:
Launched in 2014 and held annually on 13 October, World Thrombosis Day (WTD) aims to increase public, healthcare professional and health care systems' awareness of thrombosis and, ultimately, to reduce deaths and disabilities from thromboembolic disease through a greater awareness of its causes, risk factors, signs and symptoms, and evidence-based prevention and treatment. WTD's mission supports the World Health Assembly's global target of reducing premature deaths by non-communicable disease by 25 percent by 2025, as well as the WHO global action plan for the prevention and control of non-communicable diseases in the 2013-2020 timeframe. Unrestricted corporate grants to help support WTD come from Bayer HealthCare, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb/Pfizer Alliance, Daiichi Sankyo, Janssen, Portola Pharmaceuticals, Cardinal Health, Siemens, Aspen, Instrumentation Laboratory, Precision BioLogic, Roche and Stago. Visit www.worldthrombosisday.org for more information.

About the ISTH:
Founded in 1969, the International Society on Thrombosis and Haemostasis (ISTH) is the leading worldwide not-for-profit organization dedicated to advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders. The ISTH is an international membership organization with nearly 5,000 clinicians, researchers and educators working together to improve the lives of patients in more than 90 countries around the world. Among its highly regarded activities and initiatives are education and standardization programs, research activities, meetings and conferences, peer-reviewed publications and expert committees. Visit ISTH online at www.isth.org.

Media Inquiries:
Barbara Krolak, Relationship and Campaign Specialist
International Society on Thrombosis and Haemostasis
[email protected]  

SOURCE International Society on Thrombosis and Haemostasis (ISTH)


These press releases may also interest you

at 03:30
Vicore Pharma Holding (STO:VICO)Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPFAdditional presentations include preclinical and translational data reflecting...

at 03:13
Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com. The Swedish version of the Report is also available on the company's website in European Single Electronic Format (ESEF). A PDF version is...

at 03:05
Surge has just closed its second round of funding, raising ?7.5 million. The round was led by Eurazeo with the participation of Kima, Teampact, and MH Innov', as well as the support of historical funds Boutique Venture, HCVC, and 50 Partners Santé....

at 03:00
CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who...

at 03:00
An analysis by the World Wildlife Fund (WWF) suggests that the average person ingests as many as 5 grams of microplastics weekly ? that's the equivalent of eating a whole credit card. While the exact effects of plastics on human health are still...

at 03:00
Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the...



News published on and distributed by: